Your browser doesn't support javascript.
loading
Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project.
Gallacher, John; de Reydet de Vulpillieres, Frederic; Amzal, Billy; Angehrn, Zuzanna; Bexelius, Christin; Bintener, Christophe; Bouvy, Jacoline C; Campo, Laura; Diaz, Carlos; Georges, Jean; Gray, Alastair; Hottgenroth, Antje; Jonsson, Pall; Mittelstadt, Brent; Potashman, Michele H; Reed, Catherine; Sudlow, Cathie; Thompson, Robin; Tockhorn-Heidenreich, Antje; Turner, Andrew; van der Lei, Johan; Visser, Pieter Jelle.
Afiliação
  • Gallacher J; Department of Psychiatry, University of Oxford, Oxford, UK.
  • de Reydet de Vulpillieres F; Novartis Pharma AG, Basel, Switzerland.
  • Amzal B; Analytica Laser, London, UK.
  • Angehrn Z; Analytica Laser, London, UK.
  • Bexelius C; F. Hoffmann-La Roche, Basel, Switzerland.
  • Bintener C; Alzheimer Europe, Luxembourg, Luxembourg.
  • Bouvy JC; National Institute for Health and Care Excellence (NICE), London, UK.
  • Campo L; Eli Lilly Italy S.p.A., Sesto Fiorentino, Italy.
  • Diaz C; Synapse Research Management Partners SL, Barcelona, Spain.
  • Georges J; Alzheimer Europe, Luxembourg, Luxembourg.
  • Gray A; Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Hottgenroth A; Lilly Deutschland GmbH, Bad Homburg, Germany.
  • Jonsson P; National Institute for Health and Care Excellence (NICE), London, UK.
  • Mittelstadt B; Oxford Internet Institute, University of Oxford, Oxford, UK.
  • Potashman MH; Biogen, Cambridge, MA, USA.
  • Reed C; Eli Lilly and Company Ltd., Windlesham, UK.
  • Sudlow C; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
  • Thompson R; Biogen, Zug, Switzerland.
  • Tockhorn-Heidenreich A; Eli Lilly and Company Ltd., Windlesham, UK.
  • Turner A; Biogen, Cambridge, MA, USA.
  • van der Lei J; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Visser PJ; Maastricht University, Maastricht, and VU University Medical Center, Amsterdam, Netherlands.
J Alzheimers Dis ; 67(2): 495-501, 2019.
Article em En | MEDLINE | ID: mdl-30584137
ABSTRACT
ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicina Baseada em Evidências / Doença de Alzheimer Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Aged80 / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicina Baseada em Evidências / Doença de Alzheimer Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Aged80 / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article